| Code | 92669 | ||||||||||
| MA number | 21/0251/05-S | ||||||||||
| Product Form: | tbl dsp 42x25 mg (blis.PVDC/Al) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||||
| MAH, country: | Teva B.V., Netherland | ||||||||||
| Therapeutic Class: | 21 - ANTIEPILEPTICA, ANTICONVULSIVA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Container: | blister PVDC/Alu | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 23.08.2005 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| PIL: |
PIL_Lamotrigin Actavis_01.2025.pdf
|
| SPC: |
SPC_Lamotrigin Actavis_01.2025.pdf
|
| Safety feature | Yes |
| Data update: | 15.03.2018 |
